The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of gemcitabine, ifosfamide, and oxaliplatin (GIFOX) as upfront treatment for high-risk, non-anaplastic large cell, peripheral T-cell lymphomas.
Gaetano Corazzelli
No relevant relationships to disclose
Gianpaolo Marcacci
No relevant relationships to disclose
Ferdinando Frigeri
No relevant relationships to disclose
Gaetana Capobianco
No relevant relationships to disclose
Francesco Volzone
No relevant relationships to disclose
Cristina Becchimanzi
No relevant relationships to disclose
Daniela Donnarumma
No relevant relationships to disclose
Rosa Azzaro
No relevant relationships to disclose
Rosaria De Filippi
No relevant relationships to disclose
Filippo Russo
No relevant relationships to disclose
Antonio Pinto
No relevant relationships to disclose